Literatur
- 1
EAFT (European Atrial
Fibrillation Trial) Study Group .
Secondary prevention
in non-rheumatic atrial fibrillation after transient ischaemic attack or
minor stroke.
Lancet.
1993;
342
1255-1262
- 2
Harenberg J, Huhle G, Piazolo L, Giese C, Heene D L.
Long-term
anticoagulation of outpatients with adverse events to oral anticoagulants using
low-molecular-weight heparin.
Semin Thromb Hemost.
1997;
23
167-172
- 3
Shulman R I.
Assessment
of low-molecular-weight heparin trials in cardiology.
Pharmacol Ther.
2000;
87
1-9
- 4
Stellbrink C, Hanrath P, Nixdorff U, Hofmann T, Lehmacher W, Kuhle K, Fetsch T, Grewe R,
Schmidt-Lucke J A.
Low
molecular weight heparin for prevention of thromboembolic complications
in cardioversion-rationale and design of the ACE study (Anticoagulation
in Cardioversion using Enoxaparin).
Z Kardiol.
2002;
91
249-254
Autor
Priv.-Doz. Dr. Uta C. Hoppe
Klinik III für Innere Medizin der Universität
zu Köln
Joseph-Stelzmann-Str. 9
50924
Köln
